Collaborations & Alliances

PTC Therapeutics, Odylia Therapeutics Enter Gene Therapy Alliance

Expands PTC's gene therapy portfolio to rare ophthalmic diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PTC Therapeutics, Inc. and Odylia Therapeutics entered a strategic collaboration to develop novel gene therapies in rare inherited retinal diseases (IRDs) utilizing the Anc80 vector system developed by researchers at Massachusetts Eye and Ear. The collaboration augments PTC’s expertise in localized gene therapy applications in the Central Nervous System (CNS) with the ophthalmic experience at Odylia across a broad portfolio of IRD targets. The lead program in the collaboration will be RP-G...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters